Temuterkib mesylate

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameTemuterkib mesylate
Drug Alias NameLY-3214996LY3518429
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteEli Lilly And CompanyThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesThe Netherlands Cancer Institute
Active IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[16] 
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, B-Cell, Marginal Zone +[5] 

Other Information

ATC CodeN/A
Related LinksN/A